Background: Advanced gastric cancer (aGC) has a high global incidence and a high mortality rate and because of its high malignancy and heterogeneity, the existing methods for prognosis are limited, and a new treatment model is necessary. Circulating tumor cells (CTCs) could be considered as a "liquid biopsy" for tumor diagnosis and for monitoring treatment responses and predicting clinical outcome. Clinical studies support the efficacy of programmed cell death 1 (PD-1) immunotherapy in a subset of aGC. Methods: Cell capture efficiency, as described by the CanPatrol CTC enrichment technique, was validated using artificial blood samples as well as blood samples from 32 aGC patients. Clinicopathologic data of patients were collected from the hospital information system. We used CanPatrol for CTC isolation, classification, and clinical analysis. Results: A cell capture efficiency of >80% was achieved. Significant correlation was observed between CTC enumeration and clinicopathology parameters, including the Lauren classification (r=0.470, P=0.008), perineural invasion (r=0.393, P=0.029), TNM stage (r=0.740, P<0.001), and Ki-67 level (r=0.510, P=0.005). When compared to the traditional methods, monitoring CTC subtypes exhibits higher sensitivity of evaluating the disease status. Enumeration of epithelial CTC subset and its relative abundance in the total CTC pool are highly correlated with clinical efficacy. CTC programmed cell death ligand-1 (PD-L1) could be successfully detected for immunotherapy in addition to PD-L1 immunohistochemistry and microsatellite instability. Conclusion: We provide a new method that allows for the simple and effective detection of CTCs in aGC. It has potential clinical applications in monitoring prognosis and guiding future individualized immunotherapy. Keywords: CTC enumeration, clinical response prediction, subgroup analysis, immune checkpoint therapy
Introduction
Gastric cancer (GC) is one of the most common malignancies and the second leading cause of cancer-related deaths worldwide. [1] [2] [3] [4] The early clinical symptoms of GC are insidious and atypical. Hence, at the time of consultation, more than 60% of the patients are found to have locally advanced or advanced cancer. The 5-year survival rate is only 2-15%. 5 Patients with unresectable advanced and recurrent gastric cancer have poor prognosis, in spite of recent advances in chemotherapy, including the use of molecular targeted drugs such as trastuzumab and ramucirumab. 6 Therefore, new therapeutic strategies based on new antineoplastic drugs are important for the treatment of advanced gastric cancer (aGC).
Immune checkpoint blockade, as a new molecular targeted therapy, has attracted attention in patients with melanoma, 7, 8 lung cancer, 9,10 gastric cancer, 11, 12 , and other malignant tumors. 13, 14 However, clinical trials with PD-1 monoclonal antibodies such as pembrolizumab or nivolumab have shown a fairly wide response rate (10-26%) in GC patients without selective biomarkers. 15, 16 A phase III study in the Asian population ATTRACTION-02 (NCT02267343) showed that the median survival time of patients treated with nivolumab was only extended from 4.1 months to 5.3 months. 16, 17 In another study, KEYNOTE-059, the effective rate of pembrolizumab monotherapy was found to be only 11.5%. 15 Hence, in order to enhance the efficacy of anti-PD-1 therapy in GC, identification of predictive biomarkers and screening of the target population is urgently needed. Circulating tumor cells (CTCs), regarded as "liquid biopsy", 18 provide alternative access to solid tumors. This enables serial sampling of the tumor and thereby allows us to study the tumor variations throughout the treatment regime, which in turn is crucial for the discovery of new drugs and personalized therapy. 19 Noninvasive liquid biopsy using blood specimens is clinically attractive because it is a simple sampling tool offering reproducible sampling and is more representative of the entire body state, thus overcoming the challenge of accurately representing the heterogeneity of tumors. 20, 21 However, detection and characterization of
CTCs are still technically challenging because these cells are extremely rare and mixed with a large number of hematologic cells. 19, 22 We have developed a series of CTC capture platforms and successfully used them in clinical settings. [23] [24] [25] [26] [27] But some limitations of the above methods (i.e., complex procedures, loss of CTC subpopulations) have restricted its further clinical use. In this study, we use CanPatrol ® , a CONFORMITE EUROPEENNE (CE)-certified CTC enrichment technique, 28 for rare cancer cell isolation and their analysis in a clinical setting. Results showed that the capture efficiency of >80% can be achieved through the use of CanPatrol. The five-color immunocytochemistry method was used to identify and enumerate the different CTC subsets, including fluorescently labeled EpCAM/cytokeratin, anti-CD45, PD-L1, vimentin, and DAPI-stained nuclei. Given the high sensitivity and subgroup analysis capability of this method, we validated the ability of isolation and enumeration of CTCs in 32 aGC patients and tested its potential utility in monitoring a clinical response to treatment. In this study, we aimed to evaluate the prognostic value of cancer cell counting during anticancer treatment in patients with GC. In addition, in order to better select GC patients who might benefit most from immune checkpoint therapy, we investigated the relationship between specific CTC subtypes and the efficacy of immunotherapy, as well as the change of CTC phenotype during chemotherapy. 
Materials And Methods

Cell Lines And Patient Samples
PD-L1 IHC, CTC-PDL1, And MSI Status Determination
Tissue microarray (TAM) was prepared and detected for the expression of PD-L1, MLH1 by immunohistochemical method in Department of Pathology, The Second Xiangya Hospital of Central South University. Anti-human PD-L1 mAb and anti-MLH1 mAb were purchased from Abcam. DAB kit was supplied by Beijing Suolaibao Technology Co., Ltd，Beijng, China. Tissue microarray was put into oven and waxed at 60°C for 1 hr. After dewaxing, EDTA solution was used to repair the antigen, and then the chip was put into endogenous peroxidase blocker to block for 15 mins. The antibody was incubated at room temperature according to the recommended concentration of the antibody instructions. Finally, the DAB kit was used to color and hematoxylin was used to re-stain. Results were statistically analyzed with clinic response.
PD-L1 IHC
Five high-power visual fields (×200 times) were randomly selected in tumor cells and tumor stroma with yellow to brown granules in the cytoplasm or cell membrane, respectively. The scoring criteria of staining intensity of positive cells were as follows: no staining was 0 points. The scores of light yellow, light brown, and brown were 1, 2, and 3, respectively, and the scores of positive cell density were as follows: the number of positive cells ≤70% was 1 point, 71% 80% was 2 points, 81%-90% was 3 points, and >90% was 4 points. Multiplication of cell staining intensity and density scores ≥6 scores as positive expression.
CTC-PD-L1
The proportion of PD-L1-positive cells in total CTCs in peripheral blood of 5 mL gastric cancer patients was counted. Positive score criteria were 0 for nonpositive cells, 1 for positive cells (<20%), 2 for positive cells (20%~50%), and 3 for positive cells (>50%). The final score was (≥2) for CTC-PD-L1-positive expression.
MSI
Each slice was randomly selected from five high-power visual fields with high positive rate. 100 cells were counted in each visual field. Positive score criteria were 0 for nonpositive cells, 1 for positive cells (≤10%), 2 for positive cells (10~50%), 3 for positive cells (50~80%), and 4 for positive cells (>80%). The grading standard of dyeing strength was 0 for colorless, 1 for light yellow, 2 for brown, and 3 for brown. The final score was multiplied by the two scores. The final score was 0 for protein deletion and (≥2) for protein-positive expression.
Data Collection
Clinicopathologic data of patients were collected from hospital information system, including gender, age, Lauren classification, differentiation degree, lymphovascular invasion, perineural invasion, tumor depth, lymph node status, metastasis status, TNM stage and the level of Ki-67, tumor markers, smoking, and alcohol history. The clinicopathological classifications of cancers were determined according to the 7th edition of the American Joint Committee on Cancer/International Union Against Cancer TNM classification system. 29 
Statistical Analyses
Categorical data displayed in a contingency table were analyzed using Fisher's exact test. Continuous data were analyzed by using the Mann-Whitney test and Kruskal-Wallis test. Spearman rank correlation analysis was used for nonparametric correlation analysis. All statistical analyses were carried out with the IBM SPSS statistical software package (IBM Inc.). P < 0.05 was considered statistically significant.
Results And Discussion
In order to study the cell capture efficiency using the CanPatrol CTC enrichment technique, a series of artificial blood samples were prepared by spiking MGC803/HepG2 cells into blood concentrations of approximately 10, 50, 100, and 200 cells 5 mL
. The assays were repeated 6 times for each sample. The results indicate that the average recovery for each sample was at least 80% and ranged from 80% to 90% ( Figure 1A and B) . These results represent a vast improvement in capture efficiency and stability compared to our previously established methods. 24−26 To validate the clinical utility of this technique, 5 mL of the peripheral blood sample from aGC patients were introduced into CanPatrol for isolating and identifying CTCs. Captured cells were stained with the following: Alexa Fluor 594-labeled EpCAM/cytokeratin (epithelial marker, red), Alexa Fluor 488-labeled Vimentin/Twist (mesenchymal marker, green), Alexa Fluor 647-labeled CD45 (leukocyte marker, bright blue), and DAPI. Based on the staining, CTCs were divided into three types, namely epithelial CTCs (E+/M-/CD45-), hybrid epithelial/mesenchymal CTCs (E+/M +/CD45-), and mesenchymal CTCs (E-/M+/CD45-) ( Figure 1C) . Compared with the previous immunostaining method, 27 this method offers higher sensitivity and lower background noise. Epithelial−mesenchymal transformation (EMT) plays an important role in cancer metastasis and drug resistance. Classification of CTC according to its EMT phenotype, which can be achieved by this method, is helpful for identifying the most aggressive CTC subsets and providing data for clinical application.
To study the clinical significance of CTCs in diagnosis, blood samples from 32 aGC patients were detected by this technique. As shown in Figure 2A , captured CTCs were stained with EpCAM, vimentin, PD-L1, and DAPI. Fluorescence microscopy was used to distinguish specifically captured CTCs (E ± /M Ç /CD45-/PD-L1 ± /DAPI+) from nonspecifically immobilized WBCs (E-/M-/CD45+/DAPI+) by comparing fluorescence and size (CTCs: 10-30 μm; 1 WBCs: <15 μm). The results of cell enumeration and clinical characteristics are shown in Figure 2B and Table 1 . Cancer cells captured from the GC patients had total counts ranging from 0 to 37 per 5 mL. In addition, the counts of epithelial CTCs ranged from 0 to 7, hybrid CTCs ranged from 0 to 34, and mesenchymal CTCs range from 0 to 9, respectively. To further evaluate the correlation of CTCs with the clinical characteristics of GC patients, a statistical analysis was performed. The result indicated that both the CTC count and positive expression rate were significantly associated with Lauren classification (Figure 2C ), perineural invasion ( Figure 2D ), M stage ( Figure 2E ), and Ki-67 level ( Figure 2F ). Spearman rank correlation analysis showed that CTC counts were highly correlated with N stage (r=0.379, P=0.033) and TNM stage (r=0.740, P<0.001) as shown in Table 2 . Moreover, there was a significant difference in the level of carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (CA199) between the positive and negative groups of CTCs (Table 3 ). Both positivity rate and CTC count were positively correlated with Lauren classification. This result may suggest that GC patients with diffuse type had a worse prognosis than patients with intestinal type because there were more tumor cells in the peripheral blood, and they were more prone to metastasis. The correlation between vascular invasion and CTC also needs to be discussed. Vascular invasion has been confirmed to be an important prognostic factor for GC. As the primary tumors continue to increase in size and compress the surrounding blood vessels, some tumor cells enter the blood circulation through the fissures in the blood vessel wall to form CTCs, and some tumor cells passively migrate into the circulation through protein hydrolysis or other structural changes in the tumor microenvironment. Because CTCs shed from the primary tumor into the blood and maintain the specific phenotype of the tumor, it is feasible to enrich CTCs by detecting specific molecular markers. However, our result showed that both the positivity rate and CTC count in patients with vascular invasion were higher than those in patients without vascular invasion, which suggests that vascular invasion may also be important for tumor cells to enter the blood circulation. This could lead to distant metastasis. Hence, CTCs could be used in conjunction with TNM stage and Ki-67 to evaluate the degree of disease progression and malignancy, respectively. To further evaluate the predictors of response with different CTC subtypes, some patients with mesenchymal CTCs (E-/M+/CD45-) were dynamically monitored during the therapeutic process. CTCs from these patients were synchronously compared with serum tumor marker levels and computed tomogram (CT) examination results according to Response Evaluation Criteria in Solid Tumors (RECIST). As shown in Figure 3A , a patient who received the SOX treatment regime (oxaliplatin plus S-1) showed a decline in E+CTC numbers, and its relative abundance in the total CTC population paralleled effective therapeutic interventions. With clinical treatments, the E+CTC count of this patient declined along with shrinking of tumor burden (PR). After 3 months, during maintenance chemotherapy with SOX, the tumor progressed (PD) and the E+CTC count increased rapidly, while the total CTC and serum CEA concentrations were both unaltered. As shown in Figure 3B , another phenomenon was observed during [30] [31] [32] we also investigated the relationship between CTC-PD-L1 expression and the clinical response to pembrolizumab in some GC patients. As shown in Figure 4A , in Patient 9 with GC, a sole microsatellite stable (MSS) patient who had a partial response after receiving 2 cycles pembrolizumab regimens, both tumor tissue immunohistochemical (IHC) staining and CTC immunofluorescence staining tested positive for PD-L1. An interesting finding for another MSS responder to pembrolizumab is shown in Figure 4B . The IHC staining showed that the tumor tissue was negative for PD-L1, but the CTC IFC signal was as varied as that of IHC staining. This result may indicate that the expression of CTC PD-L1 may overcome the heterogeneity of tumors and be more representative of the true status of the body. PD-L1-expressing CTCs in GC patients may have some role in the immunophenotypic differential diagnosis of tumors and thereby pinpoint potential candidates for anti-PD-1/PD-L1 immune checkpoint therapy. As previously reported, 30 the same phenomenon was also observed in a subtype of GC patients defined as MSI-H, who presented a heterogeneous distribution of MSI-H.
As shown in Figure 4C , Patient 16, a sole microsatellite instability high (MSI-H) and PD-L1-patient (both IHC and IFC), exhibited radiographically progressive disease according to the RECIST guidelines during pembrolizumab treatment for 3 cycles. Further histologic inspection demonstrated marked geographic heterogeneity of human mutL homolog 1 (MLH1) protein through IHC staining, with both positive and negative tumor regions. This patient had a mixture of MSI-H and MSS regions in the tumor. Instead, as shown in Figure 4D , another patient, with a homogeneous MSI-H status (MLH1+), exhibited a partial response according to the RECIST guidelines. Taken together, these findings contribute to our understanding of how to address the complexity of cancer heterogeneity and reveal how stochasticity in single-cell behaviors promotes phenotypic equilibrium in cancer cell populations. CTCs expressing PD-L1 and MSI are considered costeffective biomarkers that should be routinely detected for immunotherapy in addition to PD-L1 IHC.
Conclusion
In conclusion, effective application of this technique can allow for CTC quantification and classification for monitoring GC and predicting the treatment response. CTC enumeration, especially of M+CTCs, was significantly associated with clinical response. A close correlation was observed between the immunophenotypic and therapeutic response of CTCs to immune checkpoint therapy. CTC detection allowed the noninvasive and continuous dynamic monitoring of clinical GC patients, which suggests its potential for individualized treatment and therapeutic evaluation in the future.
